Litigation

Helsinn Healthcare S.A. et al. v. Teva Pharmaceuticals USA, Inc.

related consolidated action

14-6341

Patents at issue (1)

7947724

Summary

Listed as a related consolidated action involving Teva Pharmaceuticals USA, Inc., et al.; no further details provided.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

I'll research this case thoroughly before writing the overview.

Let me dig into the specific docket number 14-6341 and the '724 patent's role.

Case Overview and Background

Parties and product. Both plaintiffs are operating pharmaceutical companies, not NPEs or university licensors. Helsinn Healthcare S.A. is a privately held, family-owned Swiss specialty pharma group (Lugano; founded 1976) that in-licenses late-stage compounds, runs the CMC/clinical/regulatory work itself, holds the NDA, and out-licenses commercialization rights market-by-market. Roche Palo Alto LLC — successor to Syntex, which discovered palonosetron (U.S. Pat. No. 5,202,333) — co-developed the intravenous formulation and is a co-assignee of the formulation patents; it licensed palonosetron to Helsinn in 1998 and was dismissed from the consolidated D.N.J. actions in July 2016 after assigning the '094 patent to Helsinn (stipulation and order, Civ. Nos. 14-4274/14-6341 (D.N.J. July 26, 2016)). Defendants are Teva Pharmaceutical Industries Ltd. (Israel) and Teva Pharmaceuticals USA, Inc. The accused technology is Teva's ANDA No. 090713 (submitted Aug. 20, 2008), seeking approval for generic palonosetron hydrochloride injection, 0.25 mg/5 mL and 0.075 mg/1.5 mL single-use vials, as a Paragraph IV challenge to the Orange Book patents on Helsinn's Aloxi®, the reference-listed antiemetic for chemotherapy-induced (and postoperative) nausea and vomiting (FDA ANDA approval letter, Oct. 2015).

Patents and posture. The asserted family claims priority to a Jan. 30, 2003 provisional (No. 60/444,351), making Jan. 30, 2002 the on-sale-bar critical date. The patents are all drawn from one specification ("Liquid Pharmaceutical Formulations of Palonosetron"): the '724 (claims 2 and 9 — a stable aqueous palonosetron HCl IV solution at ~0.05 mg/mL, pH 4.0–6.0, buffered, with mannitol and EDTA), the '725 (claim 2, same disclosure, different scope), the '424 (claims 2, 5, 6, adding the EDTA limitation), and the '219 (claims 1, 2, 6 — fixed 0.25 mg dose in 5 mL with EDTA, method of reducing CINV; AIA-governed). A later method patent, the '094 (issued May 20, 2014; single-use 5 mL unit dose of 0.05 mg/mL palonosetron, 41.5 mg/mL mannitol, 0.5 mg/mL EDTA, citrate buffer pH 5.0±0.5, stable 24 months, administered pre-chemotherapy), is the patent actually litigated in No. 14-6341. The lead case was No. 11-3962 (D.N.J., filed July 8, 2011) against Dr. Reddy's, Sandoz and Teva; No. 14-6341 was filed Oct. 13, 2014 against Teva on the '094 patent and consolidated with No. 14-4274 (Dr. Reddy's) (docket listing). Venue in the District of New Jersey is conventional for ANDA litigation — the district maintains Local Patent Rules, the generics defendants have New Jersey commercial presences, and Helsinn's U.S. commercial affiliate, Helsinn Therapeutics (U.S.) Inc., is based in Bridgewater, N.J. The consolidated actions were captioned before Judge Mary L. Cooper (Magistrate Judge Douglas E. Arpert); the 2018 preliminary-injunction and claim-construction rulings were issued under Judge Stanley R. Chesler's docket after reassignment — I found the reassignment reflected only in later opinion captions, not in a docket entry (Hatch-Waxman bulletin, Jan. 30, 2018).

Why it matters. After an 11-day bench trial, Judge Cooper held on Nov. 16, 2015 that the '724, '725, '424 and '219 claims were valid and infringed and ordered that FDA approval of Teva's ANDA be

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

I'll research the docket, rulings, and PTAB proceedings in parallel.

Now let me dig into the '094-patent track (14-6341), the PTAB petitions, and the post-2019 disposition.

Key Legal Developments and Outcome — Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., No. 14‑6341 (D.N.J.), consolidated with No. 14‑4274

Framing note (repeat of a flagged discrepancy). The case metadata lists the '724 patent as the patent at issue in No. 14‑6341. The docket record does not support that: No. 14‑6341 (filed 2014‑10‑13) was the Teva member case on U.S. Patent No. 8,729,094, and it was consolidated with No. 14‑4274 (Dr. Reddy's) — the file in which the '094 patent was litigated and in which the '724/'725/'424/'219 patents had already been adjudicated in the lead case, No. 11‑3962. Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., Nos. 14‑4274 (SRC), 14‑6341 (SRC) (Consol.) (D.N.J.); stipulation caption and recitals in D.I. 25, No. 14‑6341. The chronology below therefore tracks both tracks: (A) the '724/'725/'424/'219 case (No. 11‑3962) and its appeals, which produced the governing invalidity ruling, and (B) the '094-patent case (Nos. 14‑4274/14‑6341) that the caption actually names.

A. Chronology

Date Event Source
2011‑07‑08 Helsinn + Roche file No. 11‑3962 (D.N.J.) against Dr. Reddy's, Sandoz and Teva under § 271(e)(2)(A), asserting claims 2 & 9 of the '724, claim 2 of the '725, claim 6 of the '424 and claims 1, 2 & 6 of the '219 against Teva's ANDA No. 090713, DRL's ANDA No. 201533 and Sandoz's ANDA No. 202521. Complaint, No. 11‑3962 (signature blocks: Saul Ewing; Paul Hastings for Helsinn; Loeb & Loeb for Roche)
2012‑11 Plaintiffs' document production completed (a fact later held material to the generics' diligence in amending invalidity contentions). D.I. 164, No. 11‑3962, CourtListener
2013‑02‑15 DRL, Teva and Sandoz move to amend invalidity contentions to add on-sale-bar and inventorship theories (based on the 2001 MGI agreements and a 1995 Syntex formulation book); motion granted over Helsinn's prejudice objection. This is the origin of the dispositive on-sale-bar defense. D.I. 164, No. 11‑3962
2013‑09‑09 Expert reports served (Spilker, Franc, Kirsch, DeLuca, Myrdal); inventor Calderari deposed 2013. Joint Appendix, No. 17‑1229, supremecourt.gov
2014‑10‑13 No. 14‑6341 filed against Teva on the '094 patent; consolidated with No. 14‑4274 (DRL, filed July 2014). PatentDocs Court Report, 2014‑10‑19
2014‑12‑31 Sandoz dismissed by consent (Dkt. 247). D.I. 360 at 2
2015‑02‑19 Claim construction order in No. 11‑3962. cited in IPR exhibit lists
2015‑04‑22 Markman opinion construing preamble language of the '219 claims (Dkt. 290) — the only true Markman ruling before trial. D.I. 360 at 2
2015‑06 11‑day bench trial before Judge Cooper (No. 11‑3962); closing arguments 2015‑08‑12. D.I. 360 at 2
2015‑07‑03 Dr. Reddy's files four IPRs on the '094 patent — IPR2015‑01550, ‑01551, ‑01553, ‑01554 (with parallel PGRs on later palonosetron patents). [Robins Kaplan, Generically Speaking (Fall 2015)](https://www.robinska

In the news

What the press has reported about this case, summarized with links to the source articles.

I'll research press coverage of this litigation across several angles.

Press coverage of Helsinn Healthcare v. Teva (D.N.J. 14‑6341) and the related Aloxi litigation

A threshold finding on scope. Search across the caption, party names, case number, and patent numbers turned up essentially no press coverage of C.A. No. 14‑6341 as a standalone case. The only item specifically reporting its filing is the weekly docket round‑up PatentDocs' "Court Report" (2014‑10‑19, also syndicated on JD Supra), which lists Helsinn Healthcare S.A. and Roche Palo Alto LLC against Teva Pharmaceuticals USA and Teva Pharmaceutical Industries, filed 2014‑10‑13 in D.N.J., and describes it as an ANDA/Paragraph IV case over U.S. Patent No. 8,729,094 ("Liquid Pharmaceutical Formulations of Palonosetron"), not the '724 patent. Trade press and legal-press coverage instead clusters around the consolidated Aloxi/palonosetron litigation (D.N.J. 11‑3962, which did assert the '724 patent) and its two appellate chapters — the Federal Circuit's 2017 invalidation and the Supreme Court's 2019 Helsinn decision.

The 2017 Federal Circuit ruling. BioCentury reported on 2017‑06‑02 that the Federal Circuit had invalidated U.S. Patent Nos. 7,947,724; 7,947,725; 7,960,424; and 8,598,219 — expressly naming the '724 patent — and framed the holding in market terms: the decision "allows competition from a generic palonosetron product from Teva," with U.S. marketing handled by Helsinn's partner Eisai. The Pharma Letter reported on 2017‑05‑02 that the panel "reversed the opinion of the District Court for the District of New Jersey" and held the claims "not valid and … not infringed," and carried a company statement that Helsinn and Eisai were "disappointed with the court's ruling" and "maintain their position that the patents protecting Aloxi are valid" — an executive statement that goes beyond the opinion itself. Earlier district-court wins also drew trade coverage: Life Sciences IP Review reported the February 2017 D.N.J. finding that Dr. Reddy's proposed generic infringed the '724, '094 and '980 patents and that the '724 claims were not invalid for written description or enablement.

The Supreme Court decision (2019‑01‑22). Law360 (Matthew Bultman, 2019‑01‑22) reported that the unanimous ruling "clarified the scope of the on-sale bar under the America Invents Act and underscored the need for inventors to file their patent applications as early as possible," and quoted Brinks Gilson & Lione shareholder Mark Remus that any change to the bar "is going to have to [come] expressly and not through implication," Lowenstein & Weatherwax's Kenneth Weatherwax that the decision "decisively reduces that uncertainty," and McAndrews Held & Malloy's Scott McBride on the need to "file early patent applications." Courthouse News Service (Erika Williams, 2019‑01‑22) led on the practical result — the Court "stripped Helsinn Healthcare of the patent and allowed rival Teva … to begin selling a generic version of the drug Aloxi" — and explained the confidential-sale issue for a general audience. Law360's Supreme Court IP Recap (Ryan Davis, 2019‑07‑02) characterized the term's patent ruling as resolving "an ongoing debate in patent circles," quoting Nutter McClennen & Fish's Ronald Cahill that the decision "provides clarity and certainty that inventors and the patent bar have been calling for," while Law Week Colorado (Julia Cardi, February 2019, reprinted by Kilpatrick Townsend) went further than the record in predicting collateral consequences, quoting Justin Krieger that the ruling "likely increases discovery costs in litigation because it opens the door to discovery requests for secret sale offers." Market impact was reported mostly downstream of Reuters: BioSpace summarized Reuters' coverage as warning the ruling "could make it easier to cancel key patents, especially among smaller drugmakers," noted that Aloxi "provided hundreds of millions of dollars for the company annually," and reported that in March 2018 Teva had already released its palonosetron injection. (I did not retrieve a Reuters URL directly; the Reuters characterizations above are as relayed by BioSpace, and the March 2018 at‑risk launch is corroborated in the court record — Helsinn's own 2015 judgment and Teva's FDA approval letter both reference an early‑launch dispute, and a Sagent filing states Teva launched at‑risk on 2018‑03‑23 over Helsinn's unsuccessful bid for an injunction.)

Where accounts diverge, and what no one reported. Framing differed materially: The Pharma Letter's May 2017 story told readers Teva "will not be able to launch a generic version of Aloxi until additional steps are taken by the Federal Circuit, the New Jersey Court and the FDA," a forecast that proved wrong when Teva launched in March 2018 after the mandate issued; Courthouse News' 2019 headline framing ("High Court Allows Generic Anti-Nausea Drug") implies the launch hinged on the January 2019 ruling, when generic entry had in fact occurred roughly ten months earlier. Analyst-style commentary is abundant but is attorney reaction rather than financial analysis: no outlet reported a damages figure, royalty, or settlement term for the Teva case, and I found no coverage of any Helsinn–Teva settlement — the only settlement figures in the public record relate to Dr. Reddy's, Sandoz, Sagent and other ANDA sponsors, and those appear in litigation filings rather than press reports. I also found no Ars Technica, The Verge, or EFF Deeplinks coverage of this dispute; the "big tech vs. patent trolls" outlets that typically cover on-sale-bar and AIA cases did not pick it up, and the coverage that exists is confined to legal trade press, pharma trade press, and wire-derived general items. Finally, note the discrepancy between the case metadata (which lists the '724 patent) and the contemporaneous docket reporting (which describes 14‑6341 as an '094-patent case subsequently folded into the consolidated Aloxi actions where the '724 patent was asserted) — the press never addressed this directly, and I could not source it beyond the docket summaries above.

Sources

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the docket and counsel appearances for this case.

Let me look at the specific docket for 14-cv-6341 and confirm which firms appeared.

Let me pull the docket-alarm page and confirm the Paul Hastings/Saul Ewing teams.

Counsel of Record — Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC

Sourcing caveat up front: PACER itself is paywalled and I could not pull the live docket sheet for 2:14-cv-06341. What follows is grounded in the plaintiffs' complaint signature blocks, the Rule 11.2/40.1 certification, the D.I. 25 stipulation of dismissal of Roche filed in No. 14-6341, the June 2015 trial transcript in the consolidated case, and the Supreme Court stay/cert papers (all linked below). No attorney below is inferred — each name appears in a filed document.

One docket note: the public docket entries I located for No. 14-6341 (filed Oct. 13, 2014, D.N.J., before Judge Mary L. Cooper) tie that member case to U.S. Patent No. 8,729,094 (the '094 patent), which was consolidated into the lead case, No. 14-4274, where the '724, '725, '424 and '219 patents were asserted. Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., Nos. 14-4274 (SRC), 14-6341 (SRC) (Consol.) (D.N.J.). The same plaintiffs' team appears across both files, so the roster below covers counsel of record for plaintiffs in this consolidated action.

1. Helsinn Healthcare S.A. — national/lead counsel: Paul Hastings LLP

Attorney Role Firm / Office Note
Joseph M. O'Malley, Jr. Lead trial counsel; argued for Helsinn at trial and in the Federal Circuit Paul Hastings LLP, 200 Park Avenue, New York, NY (complaint originally listed 75 E. 55th St.) Longtime Paul Hastings life-sciences IP litigator; first-chair in the Aloxi®/palonosetron Hatch-Waxman bench trial and the appeal that produced Helsinn v. Teva, 855 F.3d 1356 (Fed. Cir. 2017)
Eric W. Dittmann Trial team; second-chair/appearances at trial Paul Hastings LLP, New York Listed on the complaint and on the 2015 trial appearance sheet alongside O'Malley
Bruce M. Wexler Of counsel/trial team Paul Hastings LLP, New York Named in the complaint signature block as counsel for Helsinn
Isaac S. Ashkenazi Trial team (later lead day-to-day) Paul Hastings LLP, New York Appeared at the June 2015 trial; still signing Helsinn pleadings in the later Aloxi® cases (e.g., 2019 stipulation in No. 16-1683)
Young J. Park Later-stage case team Paul Hastings LLP, New York On Helsinn's Supreme Court stay papers and later Aloxi® filings
David M. Conca Complaint-stage team Paul Hastings LLP, New York Named in the 14-4274 complaint signature block
Gary Ji Complaint-stage team Paul Hastings LLP, New York Named in the 14-4274 complaint signature block
Angela C. Ni Complaint-stage team Paul Hastings LLP, New York Named in the 14-4274 complaint signature block
Maria C. Nunez Later-stage case team Paul Hastings LLP, New York Named in the 2019 Helsinn stipulation of dismissal
Stephen B. Kinnaird Appellate/SCOTUS team Paul Hastings LLP, 875 15th St. N.W., Washington, DC Former DOJ appellate lawyer; listed on Helsinn's Supreme Court stay application
Anand B. Patel Appellate/SCOTUS team Paul Hastings LLP, Washington, DC Listed on the Supreme Court stay application

2. Roche Palo Alto LLC — its own counsel

Attorney Role Firm / Office Note
Mark E. Waddell Counsel for Roche Palo Alto LLC (co-plaintiff/co-assignee) Loeb & Loeb LLP, 345 Park Avenue, New York, NY Named in the complaint as Roche's separate counsel — Roche had its own Hatch-Waxman/IP litigation counsel rather than being represented by Helsinn's Paul Hastings team

Roche was dismissed from the consolidated action by stipulation dated July 26, 2016 (D.I. 25 in No. 14-6341) after assigning its rights in the '094 patent to Helsinn in May 2016; the caption was amended to remove Roche. Waddell's appearance therefore ends with that dismissal.

3. Local counsel (both plaintiffs) — Saul Ewing LLP (then Saul Ewing Arnstein & Lehr LLP)

Attorney Role Firm / Office Note
Charles M. Lizza New Jersey local counsel; signed the complaints, the D.I. 25 stipulation, and appears on the trial record Saul Ewing LLP, One Riverfront Plaza, Suite 1520, Newark, NJ Saul Ewing's life-sciences patent litigator; his firm bio credits him with the Helsinn/Roche Aloxi® trial wins over Teva and Dr. Reddy's (167-page post-trial opinion by Judge Cooper) and describes the AIA on-sale-bar issue as one of first impression
William C. Baton New Jersey local counsel Saul Ewing LLP, Newark, NJ Co-signed the complaints and the Roche dismissal stipulation with Lizza

4. Supreme Court / cert stage (Helsinn) — Williams & Connolly LLP

Attorney Role Firm / Office Note
Kannon K. Shanmugam Counsel of record before the U.S. Supreme Court in No. 17-1229; argued Dec. 4, 2018 Williams & Connolly LLP, 725 12th St. N.W., Washington, DC (now at Paul, Weiss) Argued the successful-in-part cert petition and the merits; the Court affirmed the Federal Circuit 9–0 (139 S. Ct. 628 (2019))
David M. Krinsky, Amy Mason Saharia, A. Joshua Podoll, Kathryn S. Kayali SCOTUS team Williams & Connolly LLP, Washington, DC Named with Shanmugam on Helsinn's stay application and Supreme Court filings

What I could not confirm

  • No in-house counsel for Helsinn or Roche appears in the pleadings, trial appearances, or appellate filings I reviewed.
  • I did not locate a formal notice of appearance docket entry for every Paul Hastings attorney in No. 14-6341 specifically; the names above come from the complaint/certification signature blocks, the trial transcript appearance sheet, and later filed stipulations in the consolidated action. Attorneys who signed only the complaint may have appeared pro hac vice without a separately indexed entry.
  • No sealed filings affected this list — counsel identification is not among the sealed material in this case.

Key sources: Complaint, Helsinn v. Dr. Reddy's, No. 14-4274 (D.N.J. July 7, 2014) (signature blocks listing Paul Hastings, Loeb & Loeb, and Saul Ewing) — https://www.docketalarm.com/cases/PTAB/IPR2015-01554/Inter_Partes_Review_of_U.S._Pat._8729094/docs/07-03-2015-Petitioner/Exhibit-1006-Complaint_for_Patent_Infringement__14_cv_04274.pdf ; Stipulation and Order of Dismissal of Roche Palo Alto LLC, No. 14-6341 (D.I. 25, July 26, 2016) — https://www.docketalarm.com/cases/New_Jersey_District_Court/3--14-cv-06341/HELSINN_HEALTHCARE_S.A._et_al_v._TEVA_PHARMACEUTICALS_USA_INC._et_al/docs/25.pdf ; Trial transcript appearances, June 15, 2015 (No. 11-3962) — https://www.docketalarm.com/cases/PTAB/IPR2015-01550/Inter_Partes_Review_of_U.S._Pat._8729094/docs/07-03-2015-Petitioner/Exhibit-1043-Tr_transcript_Dr_Amidon_June_15,_2015.pdf ; Helsinn Application for Stay of Mandate, No. 17A785 (Jan. 23, 2018) — https://www.docketalarm.com/cases/Supreme_Court/17A785/Helsinn_Healthcare_S.A._Applicant_v._Teva_Pharmaceuticals_USA_Inc._et_al/docs/01-23-2018-Application_for_a_stay_of_mandate/0123131709813-Main_Document.pdf ; Joint Appendix, No. 17-1229 — https://www.supremecourt.gov/DocketPDF/17/17-1229/60445/20180823120525348_Helsinn%20joint%20appendix%20FINAL.PDF ; Saul Ewing bio, Charles M. Lizza — https://www.saul.com/professionals/charles-m-lizza/experience .

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the docket and related sources for Teva's counsel of record.